Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes

G Daniel Brooks The Asthma and Allergy Center, Bellevue, NE, USACorrespondence: G Daniel BrooksThe Asthma and Allergy Center, 3503 Samson Way, Suite 108, Bellevue, NE 68123, USATel +1-402-592-2055Fax +1-402-592-2419Email gdbrooks@asthmaandallergycenter.comAbstract: Uncontrolled asthma continues to b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Brooks GD
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	allergic asthma dupilumab eosinophils nitric oxide comorbidity Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/15454419d7904ee6b5f4dbc3c7fab253
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:15454419d7904ee6b5f4dbc3c7fab253
record_format	dspace
spelling	oai:doaj.org-article:15454419d7904ee6b5f4dbc3c7fab2532021-12-02T12:10:29ZUpdated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes1178-203Xhttps://doaj.org/article/15454419d7904ee6b5f4dbc3c7fab2532020-03-01T00:00:00Zhttps://www.dovepress.com/updated-evaluation-of-dupilumab-in-the-treatment-of-asthma-patient-sel-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XG Daniel Brooks The Asthma and Allergy Center, Bellevue, NE, USACorrespondence: G Daniel BrooksThe Asthma and Allergy Center, 3503 Samson Way, Suite 108, Bellevue, NE 68123, USATel +1-402-592-2055Fax +1-402-592-2419Email gdbrooks@asthmaandallergycenter.comAbstract: Uncontrolled asthma continues to be a problem for many patients with moderate-to-severe allergic asthma. Dupilumab, which blocks the receptors for interleukin-4 and interleukin-13, has been effective in reducing asthma exacerbations, improving forced expiratory volume in one second (FEV1), and reducing oral corticosteroid use. When selecting patients for dupilumab, it is important to consider entry criteria for the original studies, subgroups that have responded best, and the presence of comorbid diseases that may also respond to dupilumab. Factors that were considered when selecting patients likely to respond to dupilumab in asthma studies include: failure of moderate or high dose inhaled steroids in combination with an additional controller medication, baseline FEV1 reversibility of 12% or greater, and Asthma Control Questionnaire > 1.5. The baseline characteristics that predicted a better response to dupilumab included blood eosinophils > 150 cells/mm3 and fractional exhaled nitric oxide > 25 parts per billion. Comorbidities that may also respond to treatment with dupilumab include atopic dermatitis, chronic rhinosinusitis, and allergic rhinitis. A combination of these factors should be considered when selecting the patients most likely to benefit from dupilumab.Keywords: allergic asthma, dupilumab, eosinophils, nitric oxide, comorbidityBrooks GDDove Medical Pressarticleallergic asthmadupilumabeosinophilsnitric oxidecomorbidityTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 16, Pp 181-187 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	allergic asthma dupilumab eosinophils nitric oxide comorbidity Therapeutics. Pharmacology RM1-950
spellingShingle	allergic asthma dupilumab eosinophils nitric oxide comorbidity Therapeutics. Pharmacology RM1-950 Brooks GD Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes
description	G Daniel Brooks The Asthma and Allergy Center, Bellevue, NE, USACorrespondence: G Daniel BrooksThe Asthma and Allergy Center, 3503 Samson Way, Suite 108, Bellevue, NE 68123, USATel +1-402-592-2055Fax +1-402-592-2419Email gdbrooks@asthmaandallergycenter.comAbstract: Uncontrolled asthma continues to be a problem for many patients with moderate-to-severe allergic asthma. Dupilumab, which blocks the receptors for interleukin-4 and interleukin-13, has been effective in reducing asthma exacerbations, improving forced expiratory volume in one second (FEV1), and reducing oral corticosteroid use. When selecting patients for dupilumab, it is important to consider entry criteria for the original studies, subgroups that have responded best, and the presence of comorbid diseases that may also respond to dupilumab. Factors that were considered when selecting patients likely to respond to dupilumab in asthma studies include: failure of moderate or high dose inhaled steroids in combination with an additional controller medication, baseline FEV1 reversibility of 12% or greater, and Asthma Control Questionnaire > 1.5. The baseline characteristics that predicted a better response to dupilumab included blood eosinophils > 150 cells/mm3 and fractional exhaled nitric oxide > 25 parts per billion. Comorbidities that may also respond to treatment with dupilumab include atopic dermatitis, chronic rhinosinusitis, and allergic rhinitis. A combination of these factors should be considered when selecting the patients most likely to benefit from dupilumab.Keywords: allergic asthma, dupilumab, eosinophils, nitric oxide, comorbidity
format	article
author	Brooks GD
author_facet	Brooks GD
author_sort	Brooks GD
title	Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes
title_short	Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes
title_full	Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes
title_fullStr	Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes
title_full_unstemmed	Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes
title_sort	updated evaluation of dupilumab in the treatment of asthma: patient selection and reported outcomes
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/15454419d7904ee6b5f4dbc3c7fab253
work_keys_str_mv	AT brooksgd updatedevaluationofdupilumabinthetreatmentofasthmapatientselectionandreportedoutcomes
_version_	1718394614851829760

Updated Evaluation of Dupilumab in the Treatment of Asthma: Patient Selection and Reported Outcomes

Ejemplares similares